Tilman Schubert1,2, Utaroh Motosugi1,3, Sonja Kinner1,4, Timothy J Colgan1, Samir D Sharma1, Scott Hetzel5, Shane Wells1, Camilo A Campo1, Scott B Reeder1,6,7,8,9. 1. Department of Radiology, University of Wisconsin-Madison, Madison, Wisconsin, USA. 2. Clinic of Radiology and Nuclear Medicine, Basel University Hospital, Basel, Switzerland. 3. Department of Radiology, University of Yamanashi, Yamanashi, Japan. 4. Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany. 5. Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, Madison, Wisconsin, USA. 6. Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, USA. 7. Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA. 8. Department of Emergency Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA. 9. Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Abstract
PURPOSE:Ferumoxytol (FE) has gained interest as an alternative to gadolinium-based contrast agents (GBCAs). The purpose of this study was to evaluate and optimize ferumoxytol dose and T1 weighting, in comparison to a conventional GBCA. MATERIALS AND METHODS:Twelve healthy volunteers (six women / six men, mean age 44.3 years) were recruited for this study. Scanning was performed on a clinical 3 Tesla (T) MRI system. Gadobenate dimeglumine (GD)-enhanced MRA was performed followed by FE-enhanced MRA 1 month later. Volunteers were randomly assigned to a diluted (n = 6) or undiluted (n = 6) dose of GD (0.1 mmol/kg), and to FE doses of 4 mg/kg (n = 6) or 2 mg/kg (n = 6). First pass and steady-state MRA were performed for GD- and FE-enhanced MRA. Flip-angle optimization was performed after FE administration. Quantitative analysis included relative contrast-to-noise ratio (relCNR) measurements for all acquisitions. First pass GD- and FE-enhanced MRA images were evaluated qualitatively. RESULTS:RelCNR was significantly higher with undiluted GD (31.8, 95% confidence interval [CI], 27.7-35.9) compared with diluted GD (16.2; 95% CI, 12.2-20.3; P = 0.001) and both 4 mg/kg FE (12.5; 95% CI, 8.5-16.4; P < 0.001) and 2 mg/kg FE (9.1; 95% CI, 5.1-13.2; P < 0.001) during first pass. Relative CNR did not decrease with FE 5 min postinjection compared with GD. Flip-angle analysis revealed relative CNR-peaks at 30° for FE 4 mg/kg and at 20° for FE 2 mg/kg. Diluted GD (P = 0.013) and FE 4 mg/kg (P = 0.01) revealed significantly higher image quality scores compared with undiluted GD during first pass. CONCLUSION: This study shows an equivalent image quality of FE and GD for first pass MRA even though GD showed significantly higher relative CNR. LEVEL OF EVIDENCE: 1 Technical Efficacy: Stage 2 J. MAGN. RESON. IMAGING 2017;45:1617-1626.
RCT Entities:
PURPOSE:Ferumoxytol (FE) has gained interest as an alternative to gadolinium-based contrast agents (GBCAs). The purpose of this study was to evaluate and optimize ferumoxytol dose and T1 weighting, in comparison to a conventional GBCA. MATERIALS AND METHODS: Twelve healthy volunteers (six women / six men, mean age 44.3 years) were recruited for this study. Scanning was performed on a clinical 3 Tesla (T) MRI system. Gadobenate dimeglumine (GD)-enhanced MRA was performed followed by FE-enhanced MRA 1 month later. Volunteers were randomly assigned to a diluted (n = 6) or undiluted (n = 6) dose of GD (0.1 mmol/kg), and to FE doses of 4 mg/kg (n = 6) or 2 mg/kg (n = 6). First pass and steady-state MRA were performed for GD- and FE-enhanced MRA. Flip-angle optimization was performed after FE administration. Quantitative analysis included relative contrast-to-noise ratio (relCNR) measurements for all acquisitions. First pass GD- and FE-enhanced MRA images were evaluated qualitatively. RESULTS: RelCNR was significantly higher with undiluted GD (31.8, 95% confidence interval [CI], 27.7-35.9) compared with diluted GD (16.2; 95% CI, 12.2-20.3; P = 0.001) and both 4 mg/kg FE (12.5; 95% CI, 8.5-16.4; P < 0.001) and 2 mg/kg FE (9.1; 95% CI, 5.1-13.2; P < 0.001) during first pass. Relative CNR did not decrease with FE 5 min postinjection compared with GD. Flip-angle analysis revealed relative CNR-peaks at 30° for FE 4 mg/kg and at 20° for FE 2 mg/kg. Diluted GD (P = 0.013) and FE 4 mg/kg (P = 0.01) revealed significantly higher image quality scores compared with undiluted GD during first pass. CONCLUSION: This study shows an equivalent image quality of FE and GD for first pass MRA even though GD showed significantly higher relative CNR. LEVEL OF EVIDENCE: 1 Technical Efficacy: Stage 2 J. MAGN. RESON. IMAGING 2017;45:1617-1626.
Authors: Michael D Hope; Thomas A Hope; Chengcheng Zhu; Farshid Faraji; Henrik Haraldsson; Karen G Ordovas; David Saloner Journal: AJR Am J Roentgenol Date: 2015-06-23 Impact factor: 3.959
Authors: J J Westenberg; M N Wasser; R J van der Geest; P M Pattynama; A de Roos; J Vanderschoot; J H Reiber Journal: Magn Reson Imaging Date: 1999-01 Impact factor: 2.546
Authors: Bruce S Spinowitz; Annamaria T Kausz; Jovanna Baptista; Sylvia D Noble; Renuka Sothinathan; Marializa V Bernardo; Louis Brenner; Brian J G Pereira Journal: J Am Soc Nephrol Date: 2008-06-04 Impact factor: 10.121
Authors: Anjali B Nayak; Aarti Luhar; Mark Hanudel; Barbara Gales; Theodore R Hall; J Paul Finn; Isidro B Salusky; Joshua Zaritsky Journal: Pediatr Nephrol Date: 2014-09-12 Impact factor: 3.714
Authors: Fei Han; Stanislas Rapacchi; Sarah Khan; Ihab Ayad; Isidro Salusky; Simon Gabriel; Adam Plotnik; J Paul Finn; Peng Hu Journal: Magn Reson Med Date: 2014-10-09 Impact factor: 4.668
Authors: Liam Timms; Tianyi Zhou; Yue Lyu; Ju Qiao; Vishala Mishra; Rita Maria Lahoud; Gayatri Veeramani Jayaraman; Andrew S Allegretti; David Drew; Ravi T Seethamraju; Mukesh Harisinghani; Srinivas Sridhar Journal: Abdom Radiol (NY) Date: 2021-03-05